Forixiga
Eli Lilly names Ilya Yuffa as executive vice president and president, Lilly Global Markets
Patrik Jonsson, executive vice president and president, Lilly International, will retire at the end of 2026
AstraZeneca opens new global strategic R&D centre in US
The new centre will be home to nearly 2,000 world-class researchers and scientists
AstraZeneca and Daiichi Sankyo to collaborate with Summit Therapeutics
This builds on a recently announced clinical collaboration between AstraZeneca and Summit to advance cancer treatments
Roche’s fenebrutinib receives FDA filing acceptance for relapsing and primary progressive MS
If approved, this treatment would offer a new option for the nearly one million Americans living with MS
Lilly gets FDA approval for severe alopecia areata treatment for paediatric patients
Treatment with Olumiant resulted in substantial scalp hair regrowth, as well as improvements in eyebrows and eyelashes
Eli Lilly and InnoCare Pharma agree on $3.3bn drug research deal
The deal focuses on addressing critical unmet medical needs
AstraZeneca’s Tagrisso shows eight-year landmark survival in early-stage EGFR-mutated lung cancer
The results from a global phase 3 trial show the longest survival data ever reported in this setting
FDA approves Priovant’s Lisraya for dermatomyositis
This is the first oral drug treatment for this rare disease in adults
AstraZenca’s Etcamah combination therapy given FDA Accelerated Approval for breast cancer
The approval was based on phase 3 trial results showing a 56% risk reduction in disease progression
Pfizer and BioNTech’s XFG-adapted COVID-19 vaccine approved by US FDA
The 2026-2027 vaccine targets the XFG variant to more closely match current variants
Lilly to acquire Merida Biosciences in deal worth up to $2.875bn
The acquisition is to advance treatments for serious autoimmune and allergic diseases
AstraZeneca and Daiichi Sankyo’s Enhertu plus pertuzumab approved in EU as first-line treatment for breast cancer
This is the first new regimen in more than a decade for first-line treatment for this type of breast cancer